Drug Profile
Crataegus - Lichtwer Pharma
Alternative Names: LI 132Latest Information Update: 24 Dec 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Lichtwer Pharma
- Class Cardiac glycosides; Cardiotonics; Heart failure therapies; Phytotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure